Drug Profile


Alternative Names: TGFK08AA; TGFK08AA-ER; TGFK08AA-IR

Latest Information Update: 08 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Unknown
  • Developer Fabre-Kramer Pharmaceuticals
  • Class
  • Mechanism of Action Serotonin 1A receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Generalised anxiety disorder

Most Recent Events

  • 08 Jan 2016 Phase-II development for Generalised anxiety disorder is ongoing in USA (PO, controlled release)
  • 15 Jul 2010 Phase-II clinical trials in Generalised anxiety disorder in USA prior to July 2010 (PO, controlled-release & PO, immediate-release)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top